Within-patient changes in serum concentrations and patient-reported outcomes following symptom-guided enzalutamide dose reduction from 160 to 120 mg. // Clinical Genitourinary Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1558767326002028?dgcid=rss_sd_all
Within-patient changes in serum concentrations and patient-reported outcomes following symptom-guided enzalutamide dose reduction from 160 to 120 mg. Clinical Genitourinary Cancer. https://www.sciencedirect.com/science/article/pii/S1558767326002028?dgcid=rss_sd_all
“Within-patient changes in serum concentrations and patient-reported outcomes following symptom-guided enzalutamide dose reduction from 160 to 120 mg.” Clinical Genitourinary Cancer.
@article{article41299,
title = {Within-patient changes in serum concentrations and patient-reported outcomes following symptom-guided enzalutamide dose reduction from 160 to 120 mg},
journal = {Clinical Genitourinary Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1558767326002028?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...